Immutep Ltd（IMMP）财务数据IMMPImmutep Ltd

Immutep Ltd (IMMP) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Cancer Immunotherapy, accounting for 84.6% of total sales, equivalent to AUD 13.91M. Another important revenue stream is Unallocated. Understanding this composition is critical for investors evaluating how IMMP navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Immutep Ltd maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1170.97%, while the net margin is -1095.35%. These profitability ratios, combined with a Return on Equity (ROE) of -61.85%, provide a clear picture of how effectively IMMP converts its operational activities into shareholder value.

In the context of the broader market, IMMP competes directly with industry leaders such as ALDX and IRLA. With a market capitalization of $23.44M, it holds a significant position in the sector. When comparing efficiency, IMMP's gross margin of 100.00% stands against ALDX's N/A and IRLA's N/A. Such benchmarking helps identify whether Immutep Ltd is trading at a premium or discount relative to its financial performance.

The forward P/E ratio is 7.13, indicating potential for future earnings growth. The price-to-sales ratio is 1.23, suggesting reasonable valuation relative to sales. However, the negative P/E ratio of -0.21 reflects current losses, which is a concern.